Table 2.
Characteristics of NMO/SD patients with confirmed COVID-19 infection, n = 5
| Patient | Sex | Age (year) | Comorbidity | Antibody status | NMO/SD duration (year) | NMO/SD treatment (duration, year) | Corticotherapy (last 30 days) | EDSS | COVID-19 duration (days) |
COVID-19 symptoms | Clinical status (nadir) | COVID-19 test |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| #1 | F | 35 | None | AQP4-IgG + | 17 |
Azathioprine (1 y) |
No | 4 | 14 | Fever, cough, asthenia, headache, diarrhea | No limitation | SARS-CoV2 IgG + |
| #2 | F | 27 | None | AQP4-IgG + | 6 | Azathioprine (2.5y) | No | 0 | 30 | Ageusia/anosmia, asthenia, headache | Limitation of activity | Not available |
| #3 | F | 27 | Obesity | AQP4-IgG + | 11 | Mycophenolate mofetil (3y) | No | 1 | Not available | Ageusia/anosmia, cough, asthenia | No limitation | Not available |
| #4 | M | 35 | None |
AQP4-IgG− and MOG-IgG− |
2 |
Anti-CD20, Plasmapheresis (1y) |
No | 6.5 | 3 | Fever | Hospitalized without oxygen |
SARS-Cov2 IgG−, PCR + |
| #5 | F | 20 | None | AQP4-IgG + | 12 | Anti-CD20 (2.5y) | No | 3 | 7 | Ageusia/anosmia, asthenia | No limitation |
SARS-Cov2 IgG−, PCR + |
Comorbidity: hypertension, ischemic cardiopathy, obstructive sleep apnea, asthma, pulmonary embolism, diabetes, obesity (BMI > 30 kg/m2)
F female, M male, y years, d days